ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

blinatumomab

Also written as “Blinatumomab”, “MEDI-538” and “Blinatumomab (MT103)”.

Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Large B-Cell, Diffuse · Neoplasm, Residual · Lymphoma, Non-Hodgkin · Lymphoma, B-Cell, led by 4 companies.

Drug pageBlinatumomab: every studyAll 128 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 27, 202029 company-led studies, 7 open or runningNext primary completion: Nov 24, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen256 open or runningphase 4since Jul 27, 2020Jan 10, 2006Nov 24, 2027phase 2 · NCT04521231
AstraZenecaits history only20 open or runningphase 2since May 8, 2008Sep 28, 2007none ahead
Imugeneits history only10 open or runningphase 1since Sep 14, 2023Sep 14, 2023none ahead
Novartisits history only11 open or runningphase 2since Jan 13, 2026Jan 13, 2026Sep 19, 2033phase 2 · NCT07387926

Also a collaborator on its studies: BeOne Medicines, Merck and Amgen Astellas Biopharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Jan 10, 2006.

  1. Sep 6, 2016Phase 1 study in Lymphoma, Non-HodgkinNCT02961881 · 35 enrolled · United States, Australia, France and more
  2. Dec 12, 2016Phase 2 study in High-risk Diffuse Large B-Cell LymphomaNCT03023878 · 47 enrolled · United States, Canada, France and more
  3. Sep 12, 2017Phase 2 study in High-risk Diffuse Large B-cell LymphomaNCT03298412 · 10 enrolled · United States, Australia, Belgium and more
  4. Oct 23, 2017Phase 1 study in RecurrenceNCT03340766 · 31 enrolled · United States, Australia, France and more
  5. Mar 12, 2018Phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT03476239 · 121 enrolled · China
  6. Jul 27, 2020Phase 4 study in LeukemiaNCT04506086 · 10 enrolled · United States
  7. Aug 18, 2020Phase 2 study in RecurrenceNCT04521231 · 181 enrolled · United States, Argentina, Australia and more
  8. Jul 30, 2021Phase 3 study in Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)NCT04994717 · 303 enrolled · United States, Australia, Austria and more
  9. Sep 18, 2023Phase 2 study in RecurrenceNCT06054113 · 18 enrolled · China
  10. Aug 22, 2024Phase 2 study in Lupus Erythematosus, SystemicNCT06570798 · 220 planned · United States, Australia, Belgium and more
  11. Oct 17, 2024Phase 1 study in LeukemiaNCT06649006 · 6 enrolled · Japan
  12. Aug 14, 2025Phase 2 study in RecurrenceNCT07134088 · 104 enrolled · United States, Japan
  13. Oct 29, 2025Phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT07223190 · 560 planned
  14. Oct 5, 2026Primary completion moved from 2028-12-05 to 2031-03-06Date moved laterphase 2 · +27 months · NCT07134088

Ahead

  1. Nov 24, 2027Primary completion: phase 2 study in RecurrenceNCT04521231
  2. Aug 6, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06570798
  3. Sep 7, 2029Primary completion: phase 3 study in Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)NCT04994717
  4. Mar 6, 2031Primary completion: phase 2 study in RecurrenceNCT07134088

TargetBeta

CD19 →CD3E →read by rule
“T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
YK012ruleexcyte-biopharma-ltdphase 25
GSK5926371GlaxoSmithKlinephase 22
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rulecullinan-therapeutics-incphase 14
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rulecytocares-incphase 14
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 13
ATG-201ruleantengene-biologics-limitedphase 11
KT501rulekali-therapeutics-incphase 11
KT502rulekali-therapeutics-incphase 11

Studies

All 25 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07223190Precursor Cell Lymphoblastic Leukemia-Lymphoma3Not yet recruitingDec 30, 2031560
NCT07134088Recurrence · United States, Japan2Active, not recruitingMar 6, 2031104
NCT06649006Leukemia · Japan1CompletedJul 30, 20256
NCT06570798Lupus Erythematosus, Systemic · United States, Australia, Belgium and more2RecruitingAug 6, 2028220
NCT06054113Recurrence · China2Active, not recruitingJan 6, 202618
NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) · United States, Australia, Austria and more3Active, not recruitingSep 7, 2029303
NCT04521231Recurrence · United States, Argentina, Australia and more2Active, not recruitingNov 24, 2027181
NCT04506086Leukemia · United States4TerminatedJul 4, 202410
NCT03476239Precursor Cell Lymphoblastic Leukemia-Lymphoma · China3CompletedAug 21, 2019121
NCT03340766Recurrence · United States, Australia, France and more1CompletedNov 6, 202031
NCT03298412High-risk Diffuse Large B-cell Lymphoma · United States, Australia, Belgium and more2TerminatedSep 30, 201910
NCT03023878High-risk Diffuse Large B-Cell Lymphoma · United States, Canada, France and more2CompletedApr 4, 201947
NCT02961881Lymphoma, Non-Hodgkin · United States, Australia, France and more1CompletedSep 2, 202135
NCT02910063Lymphoma, B-Cell · United States, Australia, Belgium and more3CompletedMar 12, 202041
NCT02393859Precursor Cell Lymphoblastic Leukemia-Lymphoma · Argentina, Australia, Austria and more3CompletedJul 17, 2019111
NCT02412306Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia · Japan2CompletedFeb 6, 201966
NCT02013167Recurrence · United States, Australia, Austria and more3TerminatedDec 29, 2015405
NCT02000427Recurrence · United States, France, Germany and more2CompletedMay 20, 201545
NCT01741792Lymphoma, Large B-Cell, Diffuse · Germany2CompletedJul 201425
NCT01471782Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Austria, Canada and more2CompletedAug 201493
NCT01466179Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, France, Germany and more2CompletedOct 2013225
NCT01209286Precursor Cell Lymphoblastic Leukemia-Lymphoma · Germany2CompletedMar 201236
NCT01207388Burkitt Lymphoma · Austria, Belgium, France and more2CompletedFeb 2014116
NCT00560794Precursor Cell Lymphoblastic Leukemia-Lymphoma · Germany2CompletedSep 200921
NCT00274742Lymphoma, Non-Hodgkin · Germany1CompletedAug 201176

How it is read

Names in the registry

  • “Blinatumomab”, 25 entries
  • “MEDI-538”, 10 entries
  • “Blinatumomab (MT103)”, 2 entries
  • “blinatumomab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.